OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press68710.17650/1818-8346-2007-0-4-84-88RARE AND DIFFICULT HEMATOLOGIC SYNDROMESРЕДКИЕ И СЛОЖНЫЕ ГЕМАТОЛОГИЧЕСКИЕ СИНДРОМЫUse of Campath-1H in T-cell prolymphocytic leukemia (case report and review of literature)Использование препарата кэмпас при Т-клеточном пролимфоцитарном лейкозе (клинический случай и обзор литературы)DoroninV. A.ДоронинВ. А.
Russian Federation

Moscow

KrivolapovY. A.КриволаповЮ. А.
Russian Federation

St.-Petersburg

Санкт-Петербург

RyzhkovaN. V.РыжиковаН. В.
Russian Federation

Moscow

Москва

GlinshikovaO. A.ГлинщиковаО. А.
Russian Federation

Moscow

Москва

Central Railway Clinical Hospital №2 named N.A SemashkoЦКБ № 2 им. Н.А. Семашко ОАО РЖДRegional bureau of pathologyОбластное патанатомическое бюроHematology Research Center of RussiaГематологический научный центр, РАМН231120074848823112022231120222007https://oncohematology.abvpress.ru/ongm/article/view/687

This article demonstrates case report and review of literature of successful use Campath-IH in T-cell prolymphocytic leukemia.

В статье приведены обзор литературы и описание клинического случая применения препарата кэмпас при Т-клеточном пролимфоцитарном лейкозе.

T-cell prolymphocytic leukemiaCampathТ-клеточный пролимфоцитарный лейкозкэмпас1. Catovsky D., Galetto J., Okos A. et al. Prolymphocytic leukemia of B and T cell type. Lancet 1973;2:232—4.Catovsky D., Galetto J., Okos A. et al. Prolymphocytic leukemia of B and T cell type. Lancet 1973;2:232—4.2. Matutes E., Brito-Bapapulle V., Swansbury J. et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991;78:3269—74.Matutes E., Brito-Bapapulle V., Swansbury J. et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991;78:3269—74.3. Taylor A.M., Metcalfe J.A., Thick J., Mak Y.F. Leukemia and lymphoma in ataxia teleangiectasia. Blood 1996;87:423—38.Taylor A.M., Metcalfe J.A., Thick J., Mak Y.F. Leukemia and lymphoma in ataxia teleangiectasia. Blood 1996;87:423—38.4. Rosen PJ., Said J. In: Chronic leukemias and lymphomas. Biology, pathology and clinical management. G.J Schiller (ed). Humana Press; 2003. p. 79—92.Rosen PJ., Said J. In: Chronic leukemias and lymphomas. Biology, pathology and clinical management. G.J Schiller (ed). Humana Press; 2003. p. 79—92.5. Pawson R., Schulz T.F., Matutes E., Catovsky D. The human T-cell lym-photropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia 1997;11:1305—11.Pawson R., Schulz T.F., Matutes E., Catovsky D. The human T-cell lym-photropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia 1997;11:1305—11.6. Pombo de Oliveira M.S., Matutes E., Schulz T. et al. T-cell malignancies in Brazil. Clinico-pathological and molecular studies of HTLV-I-positive and-nega-tive cases. Int J Cancer 1995;60:823—7.Pombo de Oliveira M.S., Matutes E., Schulz T. et al. T-cell malignancies in Brazil. Clinico-pathological and molecular studies of HTLV-I-positive and-nega-tive cases. Int J Cancer 1995;60:823—7.7. Matutes E., Garcia Talavera J., O'Brien M., Catovsky D. The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol 1986;64: 111—24.Matutes E., Garcia Talavera J., O'Brien M., Catovsky D. The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol 1986;64: 111—24.8. Ginaldi L., Matutes E., Farahat N. et al. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Br J Haematol 1996;93:921—7.Ginaldi L., Matutes E., Farahat N. et al. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Br J Haematol 1996;93:921—7.9. Thick J., Metcalfe J.A., Mak Y.F. et al. Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients. Oncogene 1996;12:379—86.Thick J., Metcalfe J.A., Mak Y.F. et al. Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients. Oncogene 1996;12:379—86.10. Pekarsky Y., Hallas C., Croce C.M. The role of TCL1 in human T-cell leukemia. Oncogene 2001;20:5638—43.Pekarsky Y., Hallas C., Croce C.M. The role of TCL1 in human T-cell leukemia. Oncogene 2001;20:5638—43.11. Herling M., Khoury J.D., Washington L.T. et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004;104:328—35.Herling M., Khoury J.D., Washington L.T. et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004;104:328—35.12. Hoyer K.K., French S.W., Turner D.E. et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 2002;99:14392—7.Hoyer K.K., French S.W., Turner D.E. et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 2002;99:14392—7.13. Virgilio L., Lazzeri C., Bichi R. et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA 1998;95:3885—9.Virgilio L., Lazzeri C., Bichi R. et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA 1998;95:3885—9.14. Mercieca J., Matutes E., Dearden C. et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12:2588—93.Mercieca J., Matutes E., Dearden C. et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12:2588—93.15. Dyer M.J., Hale G., Hayhoe F.G., Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431—9.Dyer M.J., Hale G., Hayhoe F.G., Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431—9.16. Pawson R., Dyer M.J., Barge R. et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15:2667—72.Pawson R., Dyer M.J., Barge R. et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15:2667—72.17. Dearden C.E., Matutes E., Cazin B. et al. High remission rate in T-cell prolymphocytic leukemia with CAM-PATH-1H. Blood 2001;98:1721—6.Dearden C.E., Matutes E., Cazin B. et al. High remission rate in T-cell prolymphocytic leukemia with CAM-PATH-1H. Blood 2001;98:1721—6.